TransCode Appoints New Chair of Scientific Advisory Board
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy RNAZ?
Source: PRnewswire
- New Chair Appointment: TransCode Therapeutics has appointed Dr. Anna Moore as Chair of its Scientific Advisory Board, a globally recognized expert in molecular imaging and RNA-targeted cancer therapeutics, expected to provide strategic guidance that will enhance the company's R&D efforts and drive innovative therapies forward.
- Research Agreement Signed: The company has executed a sponsored research agreement with Michigan State University aimed at accelerating the clinical development of its pipeline candidates, particularly focusing on its lead therapeutic candidate TTX-MC138, which is anticipated to bolster its competitive position in the market.
- Therapeutic Synergy Research: The research will evaluate the combination of TTX-MC138 with Seviprotimut-L to explore potential synergies, a strategy that could enhance therapeutic efficacy and address significant unmet medical needs in oncology.
- Industry Impact: Dr. Moore's addition not only strengthens the scientific leadership of the company but may also attract greater investor interest in TransCode's future growth potential, particularly in the innovative advancements in high-risk and advanced cancer treatments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RNAZ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RNAZ
About RNAZ
TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. It is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The Company is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
TransCode Appoints New Chair of Scientific Advisory Board
- New Chair Appointment: TransCode Therapeutics has appointed Dr. Anna Moore as Chair of its Scientific Advisory Board, a globally recognized expert in molecular imaging and RNA-targeted cancer therapeutics, expected to provide strategic guidance that will enhance the company's R&D efforts and drive innovative therapies forward.
- Research Agreement Signed: The company has executed a sponsored research agreement with Michigan State University aimed at accelerating the clinical development of its pipeline candidates, particularly focusing on its lead therapeutic candidate TTX-MC138, which is anticipated to bolster its competitive position in the market.
- Therapeutic Synergy Research: The research will evaluate the combination of TTX-MC138 with Seviprotimut-L to explore potential synergies, a strategy that could enhance therapeutic efficacy and address significant unmet medical needs in oncology.
- Industry Impact: Dr. Moore's addition not only strengthens the scientific leadership of the company but may also attract greater investor interest in TransCode's future growth potential, particularly in the innovative advancements in high-risk and advanced cancer treatments.
See More
TransCode Secures $20 Million Financing for Cancer Treatment
- Financing Agreement: TransCode Therapeutics has entered into a financing agreement with an institutional investor for up to $20 million, which includes $6 million in pre-paid advances and a three-year Standby Equity Purchase Agreement, ensuring operational flexibility during the Phase 2a trial of TTX-MC138.
- Clinical Trial Progress: TTX-MC138, a first-in-class therapeutic candidate targeting miR-10b, has shown effective delivery and pharmacodynamic activity in its Phase 0 trial, with the Phase 2a trial expected to commence in Q2 2026, further advancing the company's strategic positioning in cancer treatment.
- Convertible Note Issuance: The financing will be executed through convertible promissory notes priced at 95% of face value, with an initial issuance of a $1 million note and an additional $5 million note upon shareholder approval, accruing interest at 5% annually, providing crucial funding support for the company.
- Strategic Collaboration Outlook: The financing agreement not only secures funding for TransCode but also lays the groundwork for exploring strategic collaborations, aiming to leverage the therapeutic potential of TTX-MC138 to enhance the company's position in the competitive cancer treatment market.
See More
TransCode Secures $20 Million Financing Agreement
- Financing Agreement Details: TransCode Therapeutics has entered into a financing agreement with an institutional investor for up to $20 million, which includes $6 million in prepaid advances and a three-year Standby Equity Purchase Agreement, ensuring financial flexibility as the company conducts its Phase 2a trial for TTX-MC138.
- Clinical Trial Progress: TTX-MC138, a first-in-class therapeutic candidate targeting microRNA-10b, has shown efficacy against metastatic lesions in its Phase 0 trial, with the Phase 2a trial expected to commence in Q2 2026, further validating its therapeutic potential.
- Convertible Note Issuance: The prepaid financing will be evidenced by convertible promissory notes priced at 95% of face value, accruing interest at 5% annually, providing TransCode with additional funding to support its clinical research and operations.
- Strategic Collaboration Outlook: Following the completion of the Phase 2a trial, the company plans to explore strategic collaborations with other institutions to advance the development of TTX-MC138, enhancing its competitive position in the cancer treatment market.
See More
TransCode Enters Exclusive License Agreement with Unleash Immuno Oncolytics
- Exclusive License Agreement: TransCode Therapeutics has signed an exclusive, worldwide, fully paid-up royalty-free license agreement with Unleash Immuno Oncolytics, acquiring rights to develop three drug candidates, UIO-524, UIO-525, and UIO-526, marking a strategic expansion in the field of immuno-oncology.
- Equity Payment Structure: Under the agreement, Unleash will receive 1,136,364 shares of a new series of non-voting convertible preferred stock, equivalent to 6.8% of TransCode's common stock upon conversion, enhancing Unleash's shareholder position while providing TransCode with funding to advance its R&D efforts.
- Market Opportunity: UIO-524, as a next-generation biology-driven oncolytic immunotherapy, aims to address muscle-invasive bladder cancer, a high unmet medical need, potentially opening up a multi-billion-dollar market opportunity for TransCode and strengthening its competitive position in cancer treatment.
- Clinical Trial Progress: TransCode's lead candidate, TTX-MC138, is advancing into a Phase 2a clinical trial, and the introduction of UIO-524 will further enrich its oncology pipeline, enhancing the company's market positioning and therapeutic capabilities in more aggressive disease settings.
See More
TransCode Publishes Novel Tumor Immunotherapy Research
- Innovative Immunotherapy: TransCode Therapeutics' published research introduces a novel tumor-selective immunotherapy that activates innate immune signaling within cancer cells, significantly enhancing non-invasive imaging capabilities for drug delivery, potentially transforming cancer treatment paradigms.
- Collaborative Research Findings: Conducted in collaboration with Dr. Anna Moore from Michigan State University, the study utilizes overexpressed oncogenic microRNAs as intracellular assembly templates, successfully addressing challenges associated with RIG-I agonists, including off-target immune activation and inefficient systemic delivery.
- Clinical Trial Progress: TransCode's TTX delivery platform is currently under evaluation in clinical trials, underscoring the translational feasibility of this immunotherapy approach, which may provide new treatment options for patients with high-risk and advanced cancers.
- Market Potential: TransCode's lead therapeutic candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, highlighting its unique market positioning and potential commercial value in the tumor immunotherapy landscape.
See More
TransCode Publishes TTX-MC138 Research for Glioblastoma Treatment
- Research Publication: TransCode Therapeutics, in collaboration with Michigan State University, published preclinical research on TTX-MC138 for glioblastoma treatment, demonstrating significant survival improvements, marking a crucial advancement in addressing treatment-resistant cancers.
- Efficacy Validation: The study showed that TTX-MC138 effectively delivered to human glioblastoma in murine models, inducing a five-fold increase in apoptotic activity, further validating its potential to overcome drug delivery barriers.
- Clinical Trial Progress: TTX-MC138 has completed IND studies and toxicity testing, showing good safety in Phase I trials for non-CNS cancers, with a Phase II trial anticipated to begin in the first half of 2026, advancing its clinical application.
- Strategic Implications: This research not only provides robust biological support for TransCode's RNA therapeutic platform but also showcases its broad potential in treating metastatic tumors, potentially transforming the treatment landscape for glioblastoma.
See More
TransCode Appoints New Chair of Scientific Advisory Board
- New Chair Appointment: TransCode Therapeutics has appointed Dr. Anna Moore as Chair of its Scientific Advisory Board, a globally recognized expert in molecular imaging and RNA-targeted cancer therapeutics, expected to provide strategic guidance that will enhance the company's R&D efforts and drive innovative therapies forward.
- Research Agreement Signed: The company has executed a sponsored research agreement with Michigan State University aimed at accelerating the clinical development of its pipeline candidates, particularly focusing on its lead therapeutic candidate TTX-MC138, which is anticipated to bolster its competitive position in the market.
- Therapeutic Synergy Research: The research will evaluate the combination of TTX-MC138 with Seviprotimut-L to explore potential synergies, a strategy that could enhance therapeutic efficacy and address significant unmet medical needs in oncology.
- Industry Impact: Dr. Moore's addition not only strengthens the scientific leadership of the company but may also attract greater investor interest in TransCode's future growth potential, particularly in the innovative advancements in high-risk and advanced cancer treatments.
See More
TransCode Secures $20 Million Financing for Cancer Treatment
- Financing Agreement: TransCode Therapeutics has entered into a financing agreement with an institutional investor for up to $20 million, which includes $6 million in pre-paid advances and a three-year Standby Equity Purchase Agreement, ensuring operational flexibility during the Phase 2a trial of TTX-MC138.
- Clinical Trial Progress: TTX-MC138, a first-in-class therapeutic candidate targeting miR-10b, has shown effective delivery and pharmacodynamic activity in its Phase 0 trial, with the Phase 2a trial expected to commence in Q2 2026, further advancing the company's strategic positioning in cancer treatment.
- Convertible Note Issuance: The financing will be executed through convertible promissory notes priced at 95% of face value, with an initial issuance of a $1 million note and an additional $5 million note upon shareholder approval, accruing interest at 5% annually, providing crucial funding support for the company.
- Strategic Collaboration Outlook: The financing agreement not only secures funding for TransCode but also lays the groundwork for exploring strategic collaborations, aiming to leverage the therapeutic potential of TTX-MC138 to enhance the company's position in the competitive cancer treatment market.
See More
TransCode Secures $20 Million Financing Agreement
- Financing Agreement Details: TransCode Therapeutics has entered into a financing agreement with an institutional investor for up to $20 million, which includes $6 million in prepaid advances and a three-year Standby Equity Purchase Agreement, ensuring financial flexibility as the company conducts its Phase 2a trial for TTX-MC138.
- Clinical Trial Progress: TTX-MC138, a first-in-class therapeutic candidate targeting microRNA-10b, has shown efficacy against metastatic lesions in its Phase 0 trial, with the Phase 2a trial expected to commence in Q2 2026, further validating its therapeutic potential.
- Convertible Note Issuance: The prepaid financing will be evidenced by convertible promissory notes priced at 95% of face value, accruing interest at 5% annually, providing TransCode with additional funding to support its clinical research and operations.
- Strategic Collaboration Outlook: Following the completion of the Phase 2a trial, the company plans to explore strategic collaborations with other institutions to advance the development of TTX-MC138, enhancing its competitive position in the cancer treatment market.
See More
TransCode Enters Exclusive License Agreement with Unleash Immuno Oncolytics
- Exclusive License Agreement: TransCode Therapeutics has signed an exclusive, worldwide, fully paid-up royalty-free license agreement with Unleash Immuno Oncolytics, acquiring rights to develop three drug candidates, UIO-524, UIO-525, and UIO-526, marking a strategic expansion in the field of immuno-oncology.
- Equity Payment Structure: Under the agreement, Unleash will receive 1,136,364 shares of a new series of non-voting convertible preferred stock, equivalent to 6.8% of TransCode's common stock upon conversion, enhancing Unleash's shareholder position while providing TransCode with funding to advance its R&D efforts.
- Market Opportunity: UIO-524, as a next-generation biology-driven oncolytic immunotherapy, aims to address muscle-invasive bladder cancer, a high unmet medical need, potentially opening up a multi-billion-dollar market opportunity for TransCode and strengthening its competitive position in cancer treatment.
- Clinical Trial Progress: TransCode's lead candidate, TTX-MC138, is advancing into a Phase 2a clinical trial, and the introduction of UIO-524 will further enrich its oncology pipeline, enhancing the company's market positioning and therapeutic capabilities in more aggressive disease settings.
See More
TransCode Publishes Novel Tumor Immunotherapy Research
- Innovative Immunotherapy: TransCode Therapeutics' published research introduces a novel tumor-selective immunotherapy that activates innate immune signaling within cancer cells, significantly enhancing non-invasive imaging capabilities for drug delivery, potentially transforming cancer treatment paradigms.
- Collaborative Research Findings: Conducted in collaboration with Dr. Anna Moore from Michigan State University, the study utilizes overexpressed oncogenic microRNAs as intracellular assembly templates, successfully addressing challenges associated with RIG-I agonists, including off-target immune activation and inefficient systemic delivery.
- Clinical Trial Progress: TransCode's TTX delivery platform is currently under evaluation in clinical trials, underscoring the translational feasibility of this immunotherapy approach, which may provide new treatment options for patients with high-risk and advanced cancers.
- Market Potential: TransCode's lead therapeutic candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, highlighting its unique market positioning and potential commercial value in the tumor immunotherapy landscape.
See More
TransCode Publishes TTX-MC138 Research for Glioblastoma Treatment
- Research Publication: TransCode Therapeutics, in collaboration with Michigan State University, published preclinical research on TTX-MC138 for glioblastoma treatment, demonstrating significant survival improvements, marking a crucial advancement in addressing treatment-resistant cancers.
- Efficacy Validation: The study showed that TTX-MC138 effectively delivered to human glioblastoma in murine models, inducing a five-fold increase in apoptotic activity, further validating its potential to overcome drug delivery barriers.
- Clinical Trial Progress: TTX-MC138 has completed IND studies and toxicity testing, showing good safety in Phase I trials for non-CNS cancers, with a Phase II trial anticipated to begin in the first half of 2026, advancing its clinical application.
- Strategic Implications: This research not only provides robust biological support for TransCode's RNA therapeutic platform but also showcases its broad potential in treating metastatic tumors, potentially transforming the treatment landscape for glioblastoma.
See More
